

NEW

Mepilex® XT

No matter what the wound healing challenge, Mepilex XT has it covered!

- ✓ Absorbs more fluid, and faster, than competitive foam dressings¹⁻³
- ✓ For all stages of the exudative wound healing process
- ✓ Clinically proven, economically beneficial⁸⁻⁹
- ✓ Provides longer wear time/fewer dressing changes⁸⁻⁹
- ✓ Minimizes trauma and pain to the patient through the use of Safetac Technology¹⁰⁻¹²
- ✓ A non-bordered foam dressing; ideal for cutting to fit any application



Mepilex XT Assortment*

Product Code	Size (cm)	Pcs/box	Pcs/case
211015	5 x 5	5	40
211100	10 x 10	5	70
211200	10 x 20	5	45
211300	15 x 15	5	25
211400	20 x 20	2	20
211500	20 x 50	2	12

* Packaged sterile in single packs

Cut any size or shape



Mepilex XT is a non-bordered soft silicone foam dressing: it can be cut to fit any wound, of any size, anywhere it is needed!†

† For optimal results overlap the wound bed by at least 2cm onto the surrounding skin.

REFERENCES: 1. Mölnlycke Health Care data on file report 20130104-004. 2. Mölnlycke Health Care data on file report 20130515-001. 3. Mölnlycke Health Care data on file report 20120815-004. 4. SMTL TM-390 & TM-404 Fluid Handling Capacity & Free Swell Absorption Capacity report 20130123-006. 5. SMTL TM-390 & TM-404 Fluid Handling Capacity & Free Swell Absorption Capacity report 20130729-001. 6. Upton D. *et al.* The impact of atraumatic vs conventional dressings on pain and stress in patients with chronic wounds. *Journal of Wound Care* 2012 21(5):209-215. 7. White R. Evidence for atraumatic soft silicone wound dressing use. *Wounds UK* 2005 1(3):104-109. 8. Bond E. Insights into high-viscous exudate – results of an international survey. *Wound International* 2015; 6(2): 11-13. 9. Mölnlycke Health Care; Data on file. 10. Davies, P., Rippon, M. Evidence review: the clinical benefits of Safetac technology in wound care. *Journal of Wound Care* 2008; Supplement: 3-31. 11. Santamaria N. *et al.* Clinical effectiveness of a silicone foam dressing for the prevention of heel pressure ulcers in critically ill patients; Border II Trial. *Journal of Wound Care* 2015; 24(8):340-345. 12. Santamaria N., Santamaria H. An estimate of the potential budget impact of using prophylactic dressings to prevent hospital-acquired PUs in Australia. *Journal of Wound Care* 2014; 23(11): 583-589.

Questions? Contact your local Mölnlycke Health Care Representative at: 1 800 494-5134 www.molnlycke.ca

The Mölnlycke Health Care, Mepilex XT and Safetac names and logos are registered trademarks of Mölnlycke Health Care AB.
© 2016 Mölnlycke Health Care, Gamlestadsvagen 3C, Goteborg, Sweden 40252.

CEWC00331605



Mepilex® XT
WITH SAFETAC® TECHNOLOGY

NEW



+ Absorbs fluid faster

✓ From 10 → 100 times faster*

* 10 x faster than Allevyn® Gentle and 100 x faster than Aquacel® Foam¹⁻³

+ Absorbs more fluid

✓ From 26 → 250% more fluid while competitive products failed initial viscous fluid absorption tests†

† 26% more than Allevyn® Gentle and 250% more than Aquacel® Foam¹⁻⁵

For all stages of the exudative wound healing process



It's all about the outcome



Mepilex® XT

Clinically Proven; Economically Beneficial


80% of clinicians felt that viscous exudate had an impact on dressing wear time and that wound enlargement or delay to healing were challenges.*⁸

Only
1 in 10



Only 1 in 10 clinicians agreed that their current foam dressings were effective in managing highly viscous exudate


84%



84% believe that viscous exudate influences clinical outcome

* Based on a clinical survey of almost 1,500 clinicians internationally.

Mepilex XT provides longer wear time/fewer dressing changes^{†9}



Less than 2% of patients require daily dressing changes compared to 18% of patients treated with other foam dressings

26%



Mepilex XT has been shown to provide a 26% longer wear time compared to other foam dressings

[†] Based on a 6-week, multicentre study of 1,062 patients with chronic and acute wounds.

>80

fewer dressing changes/week

100 patients treated with Mepilex XT vs. a leading competitive product could equate to >80 fewer dressing changes/week: that's **4,160 fewer dressing changes/year!**⁹

Effective wound management and increased wear time equate to better clinical outcomes and reduced cost.

Take on any challenge with Mepilex XT

A new, innovative, foam dressing, for all exuding wounds

CLINICAL CASE STUDY

venous leg ulcer

Patient/wound characteristics:

- 62-year old patient
- 14 week old venous leg ulcer
- wound size at the beginning of treatment: 7.7 cm²
- peri-wound skin showed signs of redness, maceration and dermatitis.

Treatment duration/outcome:

- 12 weeks of treatment using Mepilex XT
- consistent reduction in wound size over the treatment period
- marked improvement in the condition of the peri-wound skin
- fully healed wound post therapy.



BASELINE VISIT 14 week old leg ulcer



FINAL VISIT Fully healed after 12 weeks of treatment with Mepilex XT

Acknowledgement: photographs and case notes kindly supplied by Dr. Radovan Cech, Nemocnice Jihlava, Jihlava, Czech Republic.

The **SafetaC** TECHNOLOGY difference: Less Trauma. Less Pain™

Safetac technology is a patented adhesive technology; exclusive to Mölnlycke Health Care dressings and used in the treatment of millions of patients worldwide.¹⁰⁻¹²

Dressings with Safetac technology are atraumatic upon removal. These dressings minimize trauma to the wound and the surrounding skin, which minimizes pain to the patient and the risk of maceration by sealing the wound margins.¹⁰⁻¹²